Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immunocore Holdings (IMCR) EPS (Weighted Average and Diluted) (2023 - 2025)

Immunocore Holdings' EPS (Weighted Average and Diluted) history spans 3 years, with the latest figure at -$0.61 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 29.79% year-over-year to -$0.61; the TTM value through Dec 2025 reached -$0.71, up 30.39%, while the annual FY2025 figure was -$0.71, 30.39% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.61 at Immunocore Holdings, down from -$0.0 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.17 in Q3 2024 and bottomed at -$0.61 in Q4 2025.
  • The 3-year median for EPS (Weighted Average and Diluted) is -$0.29 (2023), against an average of -$0.24.
  • The largest annual shift saw EPS (Weighted Average and Diluted) skyrocketed 750.0% in 2024 before it crashed 102.07% in 2025.
  • A 3-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.4 in 2023, then fell by 17.5% to -$0.47 in 2024, then fell by 29.79% to -$0.61 in 2025.
  • Per Business Quant, the three most recent readings for IMCR's EPS (Weighted Average and Diluted) are -$0.61 (Q4 2025), -$0.0 (Q3 2025), and -$0.2 (Q2 2025).